FAURE, M.; CASTILLOUX, A. M.; LILLO-LE-LOUET, A.; BEGAUD, Bernard; MORIDE, Y.

doi:10.1002/cpt.1625

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

Langue

Article de revue

Ce document a été publié dans

Clinical Pharmacology and Therapeutics. 2020, vol. 107, n° 2, p. 443-451

Résumé en anglais

Using claims databases of a public healthcare program (Quebec) for the years 2010–2013, we conducted a cohort study of patients with acute ischemic stroke (AIS) to describe secondary prevention treatments and determine how they stood against practice guidelines. We compared the risk of death or AIS recurrence over 1 year in patients treated with anticoagulants, antiplatelets, and/or other cardiovascular drugs. In the month after discharge, 44.3% of the patients did not receive the recommended treatment and > 20% did not have any treatment. Untreated patients were younger, had less comorbidities, and a more severe AIS. Anticoagulants and antiplatelets were associated with a reduced risk of death or recurrence (hazard ratio (HR) 0.27; 95% confidence interval (CI) 0.20–0.36 and HR 0.25; 95% CI 0.16–0.38, respectively) compared with the untreated group. Effect size was similar for the other treatments. Findings confirm treatment benefits shown in clinical trials and emphasize the importance of AIS secondary prevention.< Réduire

Mots clés

PharmacoEpi-Drugs

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Secondary Stroke Prevention: A Population-Based Cohort Study on Anticoagulation and Antiplatelet Treatments, and the Risk of Death or Recurrence

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés

URI

DOI

Unités de recherche